Izrael - hebrejski - Ministry of Health

taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 20 mg - lenalidomide

Izrael - hebrejski - Ministry of Health

taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 25 mg - lenalidomide

Izrael - hebrejski - Ministry of Health

taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 5 mg - lenalidomide

Izrael - hebrejski - Ministry of Health

taro international ltd, israel - lenalidomide - קפסולות - lenalidomide 7.5 mg - lenalidomide

Izrael - hebrejski - Ministry of Health

neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejski - Ministry of Health

neopharm scientific ltd - lenalidomide 10 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejski - Ministry of Health

neopharm scientific ltd - lenalidomide 15 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejski - Ministry of Health

neopharm scientific ltd - lenalidomide 25 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Izrael - hebrejski - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib

Izrael - hebrejski - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 2.3 mg - ixazomib